drugset / Trial / NCT01962792
Study of BTK Inhibitor, Ibrutinib in Combination With Carfilzomib in Subjects With Relapsed and Refractory Multiple Myeloma
Non-randomizedParallel-groupOpen-labelTreatment
Summary
A MULTICENTER PHASE 1/2B STUDY OF THE BRUTON'S TYROSINE KINASE INHIBITOR, IBRUTINIB (PCI-32765), IN COMBINATION WITH CARFILZOMIB (KYPROLIS™) IN SUBJECTS WITH RELAPSED OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA
Timeline
- Start
- 2013-12
- Primary completion
- 2019-03
- Completion
- 2019-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carfilzomib | Other / unclassified | 27 mg/m2 | Intravenous |
| Subject | Carfilzomib | Other / unclassified | 36 mg/m2 | Intravenous |
| Subject | Ibrutinib | Small molecule | 560 mg | Oral |
| Subject | Ibrutinib | Small molecule | 840 mg | Oral |
| Background | Dexamethasone | Small molecule | 20 mg | Oral |